[
  {
    "ts": null,
    "headline": "What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10, reporting a strong year marked by the continued growth of Biktarvy and Descovy, along with the successful launch of Yeztugo, the world’s […]",
    "url": "https://finnhub.io/api/news?id=b3eda74faba24761cf668996bf154739b69ffe4ea490dd194e990a0a4bfac801",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771512891,
      "headline": "What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?",
      "id": 139149092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10, reporting a strong year marked by the continued growth of Biktarvy and Descovy, along with the successful launch of Yeztugo, the world’s […]",
      "url": "https://finnhub.io/api/news?id=b3eda74faba24761cf668996bf154739b69ffe4ea490dd194e990a0a4bfac801"
    }
  },
  {
    "ts": null,
    "headline": "Peering Into Gilead Sciences Inc's Recent Short Interest",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=37b09f431a303adbbf796168019dcf689b748ccd154f559ae5f94656b8f44a52",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771509626,
      "headline": "Peering Into Gilead Sciences Inc's Recent Short Interest",
      "id": 139160267,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=37b09f431a303adbbf796168019dcf689b748ccd154f559ae5f94656b8f44a52"
    }
  },
  {
    "ts": null,
    "headline": "Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?",
    "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=8db1d3198098b1e1d8ee7d2713dba4d76c47036212cd238f67e05d4e46186ff9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771509605,
      "headline": "Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?",
      "id": 139149093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=8db1d3198098b1e1d8ee7d2713dba4d76c47036212cd238f67e05d4e46186ff9"
    }
  }
]